Tucidinostat

Generic Name: Tucidinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Clinical Trials

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Chidamide
Drug: Abemaciclib
Drug: endocrinotherapy（doctor's choice）

First Posted Date: 2022-07-19

Last Posted Date: 2024-01-22

Lead Sponsor: Biyun Wang, MD

Target Recruit Count: 44

Registration Number: NCT05464173

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: chidamide
Drug: camrelizumab
Drug: capecitabine
Drug: carboplatin

First Posted Date: 2022-06-30

Last Posted Date: 2022-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT05438706

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat
Drug: Capecitabine
Drug: Endocrine Therapy

First Posted Date: 2022-06-09

Last Posted Date: 2022-11-04

Lead Sponsor: wang shusen

Target Recruit Count: 73

Registration Number: NCT05411380

Locations: 🇨🇳
Shusen Wang, Guangzhou, Gangdong, China

A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP

Phase 2

Not yet recruiting

Conditions: Thrombocytopenia

Interventions: Drug: Chidamide
Drug: HD-DXM

First Posted Date: 2022-06-09

Last Posted Date: 2022-06-09

Lead Sponsor: Shandong University

Target Recruit Count: 100

Registration Number: NCT05411874

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Capecitabine
Drug: Tucidinostat

First Posted Date: 2022-05-25

Last Posted Date: 2022-11-04

Lead Sponsor: wang shusen

Target Recruit Count: 126

Registration Number: NCT05390476

Locations: 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Guangdong, China

Chidamide Bridging for CAR-T Therapy

Phase 1

Recruiting

Conditions: Non Hodgkin's Lymphoma

Interventions: Drug: Fludarabine and cyclophosphamide
Drug: Chidamide
Biological: Anti-CD19 CAR-T cells

First Posted Date: 2022-05-11

Last Posted Date: 2024-03-06

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 120

Registration Number: NCT05370547

Locations: 🇨🇳
Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangzhou, China
🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China

and more 10 locations

Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

Phase 2

Recruiting

Conditions: T Cell Lymphoma

Interventions: Drug: Chidamide combined with BEAM

First Posted Date: 2022-05-10

Last Posted Date: 2022-09-29

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 23

Registration Number: NCT05367856

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Zanubrutinib plus R-ICE
Drug: Decitabine plus R-ICE
Drug: Chidamide plus R-ICE
Drug: Tofacitinib plus R-ICE
Drug: Pomalidomide plus R-ICE

First Posted Date: 2022-04-27

Last Posted Date: 2024-10-23

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 76

Registration Number: NCT05348213

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

Phase 1

Recruiting

Conditions: Neuroblastoma in Children

Interventions: Drug: Tucidinostat and etoposide

First Posted Date: 2022-04-21

Last Posted Date: 2024-02-07

Lead Sponsor: Yizhuo Zhang

Target Recruit Count: 30

Registration Number: NCT05338541

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, China

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Chidamide
Drug: Cladribine

First Posted Date: 2022-04-15

Last Posted Date: 2022-04-29

Lead Sponsor: Ge Zheng

Target Recruit Count: 31

Registration Number: NCT05330364

Locations: 🇨🇳
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy